Merck’s Cidara Therapeutics acquisition brings a lead program with potential to become a first-in-class drug for preventing influenza infection. A Phase 3 study is already underway, timed to coincide with the start of the flu season in the Northern Hemisphere.
The post Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention appeared first on MedCity News.
